Mauricio Gamboa: Approval of the final version of the manuscript; conception and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; participation in study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Sebastian Ramiro Gil Quírones: Approval of the final version of the manuscript; conception and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; participation in study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Conflicts of interest

None declared.

References

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2007;60:32–40.
2. Sánchez GNJ, de la Hoz F, Castaneda C. Incidencia de cáncer de piel en Colombia, años 2003–2007. Piel. 2011;26:7.
3. Brandão FV, Pereira AF, Gottijo B, Bittencourt FV. Epidemiological aspects of melanoma at a university hospital dermatology center over a period of 20 years. An Bras Dermatol. 2013;88:344–53.
4. Jung HJ, Kweon SS, Lee JB, Lee SC, Yun SJ. A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149:1281–8.
5. Li Y, Chen H, Chen G, Liu J, Zhu H, Nugasur B, et al. Trauma could as a triggering factor for development of acral lentiginous melanoma: a clinicopathologic study of 56 cases. Int J Clin Exp Pathol. 2016;9:7800–6.

John Alexander Nova, Guillermo Sánchez-Vanegas, Mauricio Gamboa, Sebastian Ramiro Gil-Quírones.

Department of Skin Cancer Teaching and Research, Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia

*Corresponding author.
E-mail: sebastian.gil@urosario.edu.co (S.R. Gil-Quírones).
Received 22 May 2019; accepted 9 November 2019
Available online 11 May 2020

https://doi.org/10.1016/j.ajb.2019.11.009
0365-0596/ © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Cutaneous metastases from primary solid and hematopoietic neoplasms at a referral hospital in Colombia: a cross-sectional study

Dear Editor,

Cutaneous metastases (CM) represent 2% of all skin tumors and they are present in up to 10% of all cancer patients. Their clinical and histopathological manifestations are variable and depend on the primary tumor, age, and sex.1

Currently in Colombia there are no CM studies registered, therefore this is a pioneering study in the country.

An observational, retrospective, cross-sectional study was conducted. Medical records were reviewed from patients with histopathologically confirmed CM at the Central Military Hospital in Bogotá, from January 2015 to June 2018. Patients with skin primary tumors and those without follow-up records of at least six months were excluded from the analysis. A database was built in Microsoft Excel including clinical and histopathological features of the primary tumor and metastases. Subsequently, a descriptive statistical analysis was carried out with the software SPSS v. 20™.

A total of 26 CM cases were collected, but five patients were excluded from the analysis due to the presence of primary tumors that originated in the skin. The average age was 56 years and 52.38% (n = 11) were males. The primary tumors most frequently associated were those originating in the breast (28.5%), followed by the bone marrow (23.8%).

The average time between symptoms onset and diagnosis of CM was 2.84 months, and the mean number of skin lesions was 3.76. The most frequent locations were chest 28.5% (n = 6) and abdomen (19%), and regarding clinical presentation, nodules 52.3% (n = 11) were the most commonly seen. CM behavior was evaluated with different immunohistochemical markers, whereupon three patients with elevated Ki-67 in the CM tissue compared to the primary tumor were identified (Table 1).

Relapse of the primary tumor before the appearance of CM was observed in 47.6% of the patients. The majority of patients (80.9%) received systemic chemotherapy, with a skin response only in 23.8% (n = 5) of all cases. Only four had an intervention for the CM (radiotherapy: three; surgery: one). The survival time after the skin diagnosis was 10.65 months.

CM are defined as a dissemination of malignant cells from a primary malignancy toward the skin, compromising the epidermis, dermis, or hypodermis.1 It occurs in up to 10.4% of all patients with cancer and represents 2% of all skin tumors.1

---

* How to cite this article: Ordóñez-Rubiano MF, Dávila-Osorio VL, Rubiano-Mojica PC, Mariño-Álvarez AM. Cutaneous metastases from primary solid and hematopoietic neoplasms at a referral hospital in Colombia: a cross-sectional study. An Bras Dermatol. 2020;95:533–5.

** Study conducted at the Central Military Hospital of Bogotá, Bogotá, Colombia.
Table 1  Clinical and histopathological correlation of cutaneous metastases.

| Primary tumor | Frequency | Gender | Age in years (m) | Primary histological diagnosis | Metastasis histological diagnosis | Immunohistochemistry | Skin location | Type of lesion |
|---------------|-----------|--------|------------------|--------------------------------|----------------------------------|-----------------------|---------------|---------------|
| Breast        | 28.5%     | 100%   | 0%               | Ductal adenocarcinoma (50%)    | Adeno-carcinoma                  | Estrogen loss: one    | Chest, scalp  | Nodules, plaques |
|               |           |        |                  |                                |                                  | Progesterone gain: one|              |               |
|               |           |        |                  |                                |                                  | CK-20 gain: one       |              |               |
|               |           |        |                  |                                |                                  | Ki-67, two patients: 10–89% and 5–30% |              |               |
| Kidney        | 9.5%      | 0%     | 100%             | Clear cell renal cell carcinoma (100%) | Metastatic clear cell renal cell carcinoma | No changes            | Scalp, finger | Nodules, pedunculated tumor |
| Lung          | 4.7%      | 100%   | 0%               | Adenocarcinoma                  | Adenocarcinoma                    | No changes            | Abdomen       | Nodule         |
| Bone marrow   | 23.8%     | 25%    | 75%              | ALL (50%), AML (50%)            | Leukemia cutis, leukemid          | No changes            | Face, abdomen, perianal area | Nodules, ulcers, plaques |
| Muscle        | 4.7%      | 0%     | 100%             | Epitheloid sarcoma              | Epitheloid sarcoma                | No changes            | Face          | Ulcerated nodule |
| Rectum        | 4.7%      | 0%     | 100%             | Adenocarcinoma                  | Adenocarcinoma                    | No changes            | Superior lip  | Nodule         |
| Parotid       | 4.7%      | 0%     | 100%             | Mucoepidermoid carcinoma        | Mucoepidermoid carcinoma          | No changes            | Scalp         | Nodules        |
| Brain         | 4.7%      | 0%     | 100%             | Glioblastoma                    | Glioblastoma                      | Ki-67: 20–40%         | Scalp         | Plaques        |
| Lymphatic     | 4.7%      | 100%   | 0%               | Follicular lymphoma             | B cell lymphoma                   | No changes            | Abdomen       | Plaque         |
| Unknown       | 9.5%      | 50%    | 50%              | Does not apply                  | Adeno-carcinoma                   | –                     | Bilateral inguinal | Tumor, nodules |

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.
Despite being an uncommon entity in daily practice, they have an important clinical significance because they usually indicate advanced disease, as in the present study. 1

In the majority of cases, the most frequently primary tumor associated with CM in women is breast cancer, while in men, excluding melanoma, it is lung cancer; nevertheless, the present study did not identify any male patients with CM from lung cancer. 1,3

In general, carcinomas are the most common metastasis-producing type of cancer but, as shown in this report, CM originate frequently in adenocarcinomas. 4

Clinically, they present a wide variety of manifestations, such as nodules, papules, plaques, tumors, and ulcers, sometimes are associated to pain, and have a tendency to affect the scalp, trunk, and neck. 2

Some morphological patterns have been defined histopathologically, and from time to time these may resemble findings of the primary malignancy, in which immunohistochemistry plays a fundamental role. 1,5

Finally, early recognition of CM has an important effect on patient prognosis, especially in those with a primary tumor of unknown origin, where histopathology can guide the diagnosis, or in patients with a recurrent tumor, where it could alert to an active cancer.

Financial support

None declared.

Authors’ contributions

Ordóñez Rubiano María Fernanda: Statistical analysis; approval of the final version of the manuscript; conception and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; participation in study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Dávila Osorio Victoria Lucía: Statistical analysis; approval of the final version of the manuscript; conception and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; participation in study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Rubiano Mojica Paula Celeste: Approval of the final version of the manuscript; drafting and editing of the manuscript; critical review of the literature; critical review of the manuscript.

Mariño Álvarez Ángela Marcela: Statistical analysis; approval of the final version of the manuscript; conception and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; participation in study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Conflicts of interest

None declared.

Acknowledgment

The authors would like to thank María Janeth Vargas Manrique, MD, Dermatopathologist at the Central Military Hospital and María Isabel González Coral, MD, Pathologist.

References

1. Alcaraz I, Cerroni L, Rütten A, Kutzner H, Requena L. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol. 2012;34:347-93.

2. Wong CY, Helm MA, Kalb RE, Helm TN, Zeitouni NC. The presentation, pathology, and current management strategies of cutaneous metastasis. N Am J Med Sci. 2013;5:499-504.

3. Schulman JM, Pauli ML, Neuhaus IM, Sanchez Rodriguez R, Taravati K, Shin US, et al. The distribution of cutaneous metastases correlates with local immunologic milieu. J Am Acad Dermatol. 2016;74:470-6.

4. Nibhoria S, Tiwana KK, Kaur M, Kumar S. A clinicopathological and immunohistochemical correlation in cutaneous metastases from internal malignancies: a five-year study. J Skin Cancer. 2014;2014:793937.

5. Choate EA, Nobori A, Worwick S. Cutaneous metastasis of Internal Tumors. Dermatol Clin. 2019;37:545-54.

María Fernanda Ordóñez-Rubiano 1, a, Victoria Lucía Dávila-Osorio 1, a, Paula Celeste Rubiano-Mojica 1, b,∗, Ángela Marcela Mariño-Alvarez 1, a

a Department of Dermatology, Central Military Hospital of Bogotá, Bogotá, Colombia
b Department of General Medicine, Universidad del Rosario, Bogotá, Colombia

∗Corresponding author.

E-mail: paula.rubiano@urosario.edu.co

(P.C. Rubiano-Mojica).

Received 1 October 2019; accepted 8 December 2019

Available online 11 May 2020

https://doi.org/10.1016/j.abd.2019.12.005
0365-0596/ © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espaia, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).